Molecular structure of Ondansetron, CAS Number: 99614-02-5
Ondansetron (CAS 99614-02-5)
See product citations (1)
Application:
Ondansetron is a serotonin 5-HT3 receptor antagonist
CAS Number:
99614-02-5
Purity:
≥99%
Molecular Weight:
293.4
Molecular Formula:
C18H19N3O
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ondansetron is a selective serotonin 5-HT3 receptor antagonist. It functions by competitively blocking the action of serotonin at the 5-HT3 receptor, located in the central and peripheral nervous systems. Ondansetron′s mode of action involves inhibiting the initiation of the vomiting reflex by preventing the binding of serotonin to its receptor. Ondansetron′s function is to target and block the 5-HT3 receptor, thereby interrupting the signal transmission that leads to nausea and vomiting. By interfering with the serotonin signaling pathway, ondansetron effectively prevents the activation of the vomiting reflex at the molecular level. This mechanism of action makes ondansetron useful for studying the role of serotonin in the regulation of nausea and vomiting in experimental models.
Ondansetron (CAS 99614-02-5) References
- Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. | Ye, JH., et al. 2001. CNS Drug Rev. 7: 199-213. PMID: 11474424
- 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. | Seynaeve, C., et al. 1991. Anticancer Drugs. 2: 343-55. PMID: 1665723
- Identification of novel ondansetron metabolites using LC/MSn and NMR. | Duan, M., et al. 2018. J Chromatogr B Analyt Technol Biomed Life Sci. 1095: 138-141. PMID: 30077093
- Pharmacokinetics of R-(-)ondansetron compared with that of S-(-)ondansetron in rats using an LC-MS/MS method. | Duan, M., et al. 2019. Biomed Chromatogr. 33: e4426. PMID: 30408206
- Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat. | Kwan, C., et al. 2020. Can J Physiol Pharmacol. 98: 431-440. PMID: 32017606
- Enantioseparation of ondansetron by countercurrent chromatography using sulfobutyl ether-β-cyclodextrin as chiral selector. | Sun, W., et al. 2021. J Sep Sci. 44: 922-930. PMID: 33284511
- Does Intravenous Ondansetron Affect the Intestinal Motility Pattern in Healthy Donkeys (Equus asinus)? | Farag, AMM. and Ibrahim, HMM. 2021. J Equine Vet Sci. 101: 103427. PMID: 33993949
- The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome. | Foth, S., et al. 2021. BMC Vet Res. 17: 222. PMID: 34154584
- The reversing effect of ondansetron on bupivacaine-induced sciatic nerve block. | Saltali, AO., et al. 2022. Niger J Clin Pract. 25: 1149-1157. PMID: 35859477
- The Possible Protective Effects of Ondansetron and Tropisetron on Optic Nerve Crush Injury in Rats. | Shayan, M., et al. 2023. Drug Res (Stuttg). 73: 88-94. PMID: 36423625
- Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study. | Mansour, M., et al. 2023. Pharmacol Rep. 75: 199-210. PMID: 36517694
- Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex. | Ito, H., et al. 1995. Neuropharmacology. 34: 631-7. PMID: 7566499
- Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. | Cubeddu, LX., et al. 1994. Am J Clin Oncol. 17: 137-46. PMID: 8141105
Inhibitor of:
AI931714, encephalopsin, GPR158, HRT3, HTR3C, HTR3D, HTR3E, METTL2, Olfr1, Olfr10, Olfr1000, Olfr1012, Olfr1013, Olfr1018, Olfr1030, Olfr1032, Olfr1039, Olfr1049, Olfr1056, Olfr1087, Olfr1100, Olfr1110, Olfr345, Olfr381, Olfr427, Olfr735, Olfr736, Olfr738, Olfr768, Olfr822, Olfr829, Olfr94, Olfr945, Olfr957, Olr1462, Olr401, Olr437, Olr851, OR2M, OR3A1, OR5K1, Peptide YY3, R7BP, Serotonin, SR, SR-1F, SR-2B, TAAR7H, TAAR9, TMEM174, TPMT, V1RB4, V1RB5, V1RB8, V1RI2, Vmn1r101, Vmn1r135, Vmn1r15, Vmn1r17, Vmn1r184, Vmn1r196, Vmn1r221, Vmn1r30, Vmn1r34, Vmn1r61, Vmn1r86, Vmn1r88, Vmn2r100, Vmn2r103, Vmn2r104, Vmn2r106, Vmn2r107, Vmn2r121, Vmn2r24, Vmn2r25, Vmn2r32, Vmn2r35, Vmn2r40, Vmn2r45, Vmn2r48, Vmn2r49, Vmn2r51, Vmn2r55, Vmn2r56, Vmn2r6, Vmn2r61, Vmn2r68, Vmn2r77, Vmn2r81, Vmn2r83, Vmn2r90, Vmn2r93, and VPS51.Activator of:
Cyp2c65, GPR111, GPR115, HTR3D, SR-3A, and SR-3B.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ondansetron, 10 mg | sc-201127 | 10 mg | $82.00 | |||
Ondansetron, 50 mg | sc-201127A | 50 mg | $333.00 |